Lenvatinib increases T-cell infiltration in tumors and inhibits immunosuppressive cells in the tumor microenvironment by inhibiting VEGFR, as well as lowering monocytes and macrophages, increasing the proportion of gamma interferon-induced CD8 + T cells, and boosting immunotherapy efficacy (26). Here, KDR is linked to neoplasm.